Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Randomized, Double-masked, Placebo-controlled Phase III Clinical Study of Conbercept Ophthalmic Injection for Patients With BRVO.

NCT03108352 is registered in ClinicalTrials.gov with Chengdu Kanghong Biotech Co., Ltd. as lead sponsor.

NCT NCT03108352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03108352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Randomized, Double-masked, Placebo-controlled Phase III Clinical Study of Conbercept Ophthalmic Injection for Patients With BRVO.
Lead sponsor
Chengdu Kanghong Biotech Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 13, 2016
Completion date
October 16, 2020
Enrollment
255 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

branch retinal vein occlusion, macular edema